NCT06172322 2024-04-23
A Phase Ib/â…¡ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1 Unknown
Clinical Trials
11 trialsNCT06047184 2023-09-21
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
BeBetter Med Inc
Phase 1 Unknown
NCT05433480 2023-07-27
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT05792410 2023-03-31
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT02983071 2023-02-15
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
G1 Therapeutics, Inc.
Phase 1/2 Unknown
NCT05504213 2022-08-17
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05140655 2021-12-01
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
Dr. Reddy's Laboratories SAS
Unknown
NCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT04796623 2021-03-15
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04355520 2020-04-21
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown